Caxton Associates (New York)’s ARS Pharmaceuticals SPRY Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Shares Change %	Capital Flow	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-43,169	Closed	-$281K	–	641
2023 Q1	$281K	Buy	43,169 +28,337	+191%	+$184K	0.04%	361
2022 Q4	$127K	Buy	+14,832	New	+$127K	0.01%	390